Actions
  • shareshare
  • link
  • cite
  • add
add
auto_awesome_motion View all 3 versions
Publication . Preprint . Other literature type . 2020

Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-SARS-CoV-2 response in mice

Katarzyna Polak; Noémie Greze; Maëlle Lachat; Delphine Merle; Steve Chiumento; Christelle Bertrand-Gaday; Bernadette Nadine Trentin; +1 Authors
Open Access
English
Published: 28 Oct 2020
Publisher: HAL CCSD
Country: France
Abstract

AbstractExtracellular vesicles (EVs) emerge as essential mediators of intercellular communication. DNA vaccines encoding antigens presented on EVs efficiently induce T-cell responses and EV-based vaccines containing the Spike (S) proteins of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) are highly immunogenic in mice. Thus, EVs may serve as vaccine platforms against emerging diseases, going beyond traditional strategies, with the antigen displayed identically to the original protein embedded in the viral membrane and presented as such to the immune system. Compared to their viral and pseudotyped counterparts, EV-based vaccines overcome many safety issues including pre-existing immunity against these vectors. Here, we applied our technology in natural EV’s engineering, to express the S proteins of SARS-CoV-2 embedded in the EVs, which mimic the virus with its fully native spikes. Immunizations with a two component CoVEVax vaccine, comprising DNA vector (DNAS-EV) primes, allowing in situ production of Spike harbouring EVs, and a boost using S-EVs produced in mammalian cells, trigger potent neutralizing and cellular responses in mice, in the absence of any adjuvants. CoVEVax would be the prototype of vaccines, where the sole exchange of the envelope proteins on EVs leads to the generation of new vaccine candidates against emerging viruses.

Subjects by Vocabulary

Microsoft Academic Graph classification: Virology Extracellular vesicle Viral membrane Immunity Biology Immune system Antigen Virus Viral envelope DNA vaccination

Subjects

[SDV]Life Sciences [q-bio], [SDV] Life Sciences [q-bio]

Related Organizations
moresidebar